Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

2/21/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MDGL alert in real time by email

CONSHOHOCKEN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced that the company will participate in the 45th Annual TD Cowen Health Care Conference on Tuesday, March 4, 2025 at 11:10 A.M. ET.

The presentation will be webcast live and may be accessed here or by visiting Madrigal's Investor Relations Events page. A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. For more information, visit www.madrigalpharma.com.

Investor Contact

Tina Ventura, [email protected]

Media Contact

Christopher Frates, [email protected]

Get the next $MDGL alert in real time by email

Date	Price Target	Rating	Analyst
6/28/2024		Neutral	Cantor Fitzgerald
6/11/2024	$382.00	Outperform	Wolfe Research
4/22/2024	$150.00	Underperform	BofA Securities
3/15/2024	$155.00 → $270.00	Sell → Neutral	B. Riley Securities
3/6/2024	$382.00	Buy	Citigroup
2/26/2024	$155.00	Neutral → Sell	B. Riley Securities
12/20/2022	$170.00 → $250.00	Outperform	Oppenheimer
12/19/2022		Underperform → Mkt Perform	Raymond James

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Chat with this insight

Recent Analyst Ratings for $MDGL

$MDGL SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Madrigal Pharmaceuticals Inc.

SEC Form 8-K filed by Madrigal Pharmaceuticals Inc.

SEC Form 144 filed by Madrigal Pharmaceuticals Inc.

$MDGL Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$MDGL FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

Cantor Fitzgerald initiated coverage on Madrigal Pharmaceuticals

Wolfe Research initiated coverage on Madrigal Pharmaceuticals with a new price target

BofA Securities initiated coverage on Madrigal Pharmaceuticals with a new price target

FDA Approval for REZDIFFRA issued to MADRIGAL PHARMACEUTICALS INC

$MDGL Press Releases

Fastest customizable press release news feed in the world

Madrigal Pharmaceuticals to Participate in the 45th Annual TD Cowen Health Care Conference

Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2024 Financial Results and Host Webcast on February 26, 2025

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

$MDGL Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$MDGL Leadership Updates

Live Leadership Updates

$MDGL Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Huntsman Carole sold $116,328 worth of shares (347 units at $335.24), decreasing direct ownership by 3% to 10,438 units (SEC Form 4)

President and CEO Sibold William John sold $531,020 worth of shares (1,584 units at $335.24), decreasing direct ownership by 3% to 54,303 units (SEC Form 4)

Pres., R&D, and CMO Taub Rebecca sold $217,236 worth of shares (648 units at $335.24), decreasing direct ownership by 0.14% to 456,662 units (SEC Form 4)

Madrigal Pharmaceuticals Appoints Dr. Michael R. Charlton as Senior Vice President, Clinical Development

Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

Baker Bros. Advisors Lp bought $22,516,577 worth of shares (101,792 units at $221.20) (SEC Form 4)

Baker Bros. Advisors Lp bought $7,548,616 worth of shares (34,578 units at $218.31) (SEC Form 4)

Baker Bros. Advisors Lp bought $12,128,340 worth of shares (64,350 units at $188.47) (SEC Form 4)

$MDGL Financials

Live finance-specific insights

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

Madrigal Announces Positive Topline Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH and Liver Fibrosis

$MDGL Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Madrigal Pharmaceuticals Inc.

SEC Form SC 13G filed by Madrigal Pharmaceuticals Inc.

SEC Form SC 13D/A filed by Madrigal Pharmaceuticals Inc. (Amendment)

Recent Analyst Ratings for
$MDGL

$MDGL
SEC Filings

$MDGL
Analyst Ratings

$MDGL
FDA approvals

$MDGL
Press Releases

$MDGL
Insider Trading

$MDGL
Leadership Updates

$MDGL
Insider Purchases

$MDGL
Financials

$MDGL
Large Ownership Changes